vs
Side-by-side financial comparison of Allegion (ALLE) and Hologic (HOLX). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $1.0B, roughly 1.0× Allegion). Hologic runs the higher net margin — 17.1% vs 13.4%, a 3.7% gap on every dollar of revenue. On growth, Allegion posted the faster year-over-year revenue change (9.7% vs 2.5%). Over the past eight quarters, Allegion's revenue compounded faster (3.5% CAGR vs 1.5%).
Allegion plc manufactures and sells mechanical and electronic security products and solutions worldwide. The company offers door closers, controls, and exit devices; locks, locksets, portable locks, and key systems and services; electronic security products and access control systems; time, attendance, and workforce productivity systems; doors and door systems; and other accessories. The company sells its products and solutions to end-users in commercial, institutional, and residential facili...
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
ALLE vs HOLX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $1.0B |
| Net Profit | $138.1M | $179.1M |
| Gross Margin | 44.0% | 56.0% |
| Operating Margin | 18.9% | 22.6% |
| Net Margin | 13.4% | 17.1% |
| Revenue YoY | 9.7% | 2.5% |
| Net Profit YoY | -6.8% | -10.9% |
| EPS (diluted) | — | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.0B | — | ||
| Q4 25 | $1.0B | $1.0B | ||
| Q3 25 | $1.1B | $1.0B | ||
| Q2 25 | $1.0B | $1.0B | ||
| Q1 25 | $941.9M | $1.0B | ||
| Q4 24 | $945.6M | $1.0B | ||
| Q3 24 | $967.1M | $988.0M | ||
| Q2 24 | $965.6M | $1.0B |
| Q1 26 | $138.1M | — | ||
| Q4 25 | $147.5M | $179.1M | ||
| Q3 25 | $188.4M | $187.2M | ||
| Q2 25 | $159.7M | $194.9M | ||
| Q1 25 | $148.2M | $-17.4M | ||
| Q4 24 | $144.1M | $201.0M | ||
| Q3 24 | $174.2M | $178.6M | ||
| Q2 24 | $155.4M | $194.5M |
| Q1 26 | 44.0% | — | ||
| Q4 25 | 44.5% | 56.0% | ||
| Q3 25 | 45.8% | 55.6% | ||
| Q2 25 | 45.6% | 56.3% | ||
| Q1 25 | 44.9% | 37.5% | ||
| Q4 24 | 44.1% | 56.8% | ||
| Q3 24 | 44.7% | 56.4% | ||
| Q2 24 | 44.4% | 55.4% |
| Q1 26 | 18.9% | — | ||
| Q4 25 | 20.3% | 22.6% | ||
| Q3 25 | 21.8% | 22.6% | ||
| Q2 25 | 21.5% | 24.9% | ||
| Q1 25 | 20.9% | -0.7% | ||
| Q4 24 | 19.5% | 22.5% | ||
| Q3 24 | 22.2% | 23.3% | ||
| Q2 24 | 21.6% | 24.1% |
| Q1 26 | 13.4% | — | ||
| Q4 25 | 14.3% | 17.1% | ||
| Q3 25 | 17.6% | 17.8% | ||
| Q2 25 | 15.6% | 19.0% | ||
| Q1 25 | 15.7% | -1.7% | ||
| Q4 24 | 15.2% | 19.7% | ||
| Q3 24 | 18.0% | 18.1% | ||
| Q2 24 | 16.1% | 19.2% |
| Q1 26 | — | — | ||
| Q4 25 | $1.70 | $0.79 | ||
| Q3 25 | $2.18 | $0.84 | ||
| Q2 25 | $1.85 | $0.86 | ||
| Q1 25 | $1.71 | $-0.08 | ||
| Q4 24 | $1.65 | $0.87 | ||
| Q3 24 | $1.99 | $0.75 | ||
| Q2 24 | $1.77 | $0.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $308.9M | $2.4B |
| Total DebtLower is stronger | $2.0B | $2.5B |
| Stockholders' EquityBook value | $2.1B | $5.2B |
| Total Assets | $5.3B | $9.2B |
| Debt / EquityLower = less leverage | 0.97× | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $308.9M | — | ||
| Q4 25 | $356.2M | $2.4B | ||
| Q3 25 | $302.7M | $2.2B | ||
| Q2 25 | $656.8M | $1.9B | ||
| Q1 25 | $494.5M | $1.6B | ||
| Q4 24 | $503.8M | $2.0B | ||
| Q3 24 | $878.9M | $2.3B | ||
| Q2 24 | $747.5M | $2.4B |
| Q1 26 | $2.0B | — | ||
| Q4 25 | $2.0B | $2.5B | ||
| Q3 25 | $2.1B | $2.5B | ||
| Q2 25 | $2.1B | $2.5B | ||
| Q1 25 | $2.0B | $2.5B | ||
| Q4 24 | $2.0B | $2.5B | ||
| Q3 24 | $2.4B | $2.5B | ||
| Q2 24 | $2.4B | $2.5B |
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.1B | $5.2B | ||
| Q3 25 | $1.9B | $5.0B | ||
| Q2 25 | $1.8B | $4.8B | ||
| Q1 25 | $1.6B | $4.6B | ||
| Q4 24 | $1.5B | $4.8B | ||
| Q3 24 | $1.6B | $5.1B | ||
| Q2 24 | $1.4B | $5.0B |
| Q1 26 | $5.3B | — | ||
| Q4 25 | $5.2B | $9.2B | ||
| Q3 25 | $5.2B | $9.0B | ||
| Q2 25 | $4.9B | $8.8B | ||
| Q1 25 | $4.6B | $8.5B | ||
| Q4 24 | $4.5B | $8.7B | ||
| Q3 24 | $5.0B | $9.2B | ||
| Q2 24 | $4.8B | $8.9B |
| Q1 26 | 0.97× | — | ||
| Q4 25 | 0.96× | 0.48× | ||
| Q3 25 | 1.07× | 0.50× | ||
| Q2 25 | 1.16× | 0.52× | ||
| Q1 25 | 1.24× | 0.55× | ||
| Q4 24 | 1.33× | 0.53× | ||
| Q3 24 | 1.53× | 0.49× | ||
| Q2 24 | 1.69× | 0.51× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $101.3M | $229.9M |
| Free Cash FlowOCF − Capex | — | $215.2M |
| FCF MarginFCF / Revenue | — | 20.5% |
| Capex IntensityCapex / Revenue | 2.0% | 1.4% |
| Cash ConversionOCF / Net Profit | 0.73× | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $101.3M | — | ||
| Q4 25 | $240.1M | $229.9M | ||
| Q3 25 | $229.5M | $355.1M | ||
| Q2 25 | $209.7M | $343.3M | ||
| Q1 25 | $104.5M | $169.4M | ||
| Q4 24 | $219.0M | $189.3M | ||
| Q3 24 | $231.9M | $367.0M | ||
| Q2 24 | $173.0M | $405.8M |
| Q1 26 | — | — | ||
| Q4 25 | $200.5M | $215.2M | ||
| Q3 25 | $209.8M | $341.4M | ||
| Q2 25 | $192.0M | $330.5M | ||
| Q1 25 | $83.4M | $153.9M | ||
| Q4 24 | $194.9M | $172.5M | ||
| Q3 24 | $212.0M | $350.6M | ||
| Q2 24 | $152.1M | $385.3M |
| Q1 26 | — | — | ||
| Q4 25 | 19.4% | 20.5% | ||
| Q3 25 | 19.6% | 32.5% | ||
| Q2 25 | 18.8% | 32.3% | ||
| Q1 25 | 8.9% | 15.3% | ||
| Q4 24 | 20.6% | 16.9% | ||
| Q3 24 | 21.9% | 35.5% | ||
| Q2 24 | 15.8% | 38.1% |
| Q1 26 | 2.0% | — | ||
| Q4 25 | 3.8% | 1.4% | ||
| Q3 25 | 1.8% | 1.3% | ||
| Q2 25 | 1.7% | 1.3% | ||
| Q1 25 | 2.2% | 1.5% | ||
| Q4 24 | 2.5% | 1.6% | ||
| Q3 24 | 2.1% | 1.7% | ||
| Q2 24 | 2.2% | 2.0% |
| Q1 26 | 0.73× | — | ||
| Q4 25 | 1.63× | 1.28× | ||
| Q3 25 | 1.22× | 1.90× | ||
| Q2 25 | 1.31× | 1.76× | ||
| Q1 25 | 0.71× | — | ||
| Q4 24 | 1.52× | 0.94× | ||
| Q3 24 | 1.33× | 2.05× | ||
| Q2 24 | 1.11× | 2.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALLE
| Allegion Americas | $809.9M | 78% |
| Allegion International | $223.7M | 22% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
